Reckitt Benckiser neurology news

Reckitt Benckiser disclosed in its 2Q14 earnings that it plans to spin out Reckitt Benckiser Pharmaceuticals Inc. - its pharmaceutical business - with a separate listing on the London Stock Exchange over the next 12 months. Last year, Reckitt said it was exploring strategic options for the business, which had 1H14 revenues of L344 million ($588.4 million) - down 8% in constant currencies from 1H13 (see BioCentury, Nov. 4, 2013). ...